Niki BioSolutions, Inc.

NIKI • Biotechnology

Movimiento fuerte

NIKI-14.84%

vs. cierre anterior $9.70

$8.26

▼ -1.44 (-14.84%)

Precio actual

ResultadosÚltimo reporte: 31 dic 2025

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$60.73M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.15Liquidez débil · 0.78Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 dic 2025, 12:00 a.m. UTCÚltima actualización de earnings: 28 abr 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$8.26

Change-14.84%

Shares Out7.35M

Market Cap$60.73M

Enterprise Value$60.80M

Beta0.00

P/E-10.78

P/B2.63

P/FCF-6.77

EV/EBITDA-12.20

EV/FCF-6.78

Earnings Yield-9.27%

Price$8.26

Change-14.84%

Shares Out7.35M

Market Cap$60.73M

Enterprise Value$60.80M

Beta0.00

P/E-10.78

P/B2.63

P/FCF-6.77

EV/EBITDA-12.20

EV/FCF-6.78

Earnings Yield-9.27%

FCF Yield-14.78%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.15

Current Ratio0.78

Quick Ratio0.78

Volume202.99K

Avg Volume0.00

EPS Surprise3.21

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

44/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

95/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.15Liquidez débil · 0.78Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

APM

Analyst sentiment

Based on 2 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 7/20/2026

Industria: Biotechnology

P/B i: 2.63

Deuda / Patrimonio i: 0.15

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje9 / 20

Deuda / Patrimonio: 0.15

Ratio corriente: 0.78

Ratio rápido: 0.78

Estado: Moderate

Advertencias

Weak Liquidity

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

Aptorum Group Limited

Aptorum Group Limited operates as a biopharmaceutical firm, primarily engaged in the identification, development, and commercialization of medicinal treatments. Its core therapeutic efforts are directed towards combating infectious diseases and various forms of cancer. The company's operations are bifurcated into two distinct divisions: Therapeutics and Non-Therapeutics. Aptorum boasts a diverse product pipeline, featuring several key candidates. In the field of oncology, SACT-1 is under development for neuroblastoma and other cancer types. For infectious diseases, SACT-COV19 is being advanced for coronavirus, while ALS-4 targets bacterial infections caused by Staphylococcus aureus, including antibiotic-resistant MRSA strains. ALS-1 is designed to address viral infections like influenza A, and ALS-2/3 focuses on gram-positive bacterial infections. Beyond these, the company is progressing NLS-1 for endometriosis, DLS-1+2 for non-small cell lung cancer (NSCLC) with specific mutations, DLS-3 as a small molecule for autoimmune conditions, and CLS-1 for obesity management. The non-therapeutic portfolio includes RPIDD, a molecular diagnostic tool for pathogens, and NativusWell DOI (NLS-2), a dietary supplement. Aptorum utilizes various innovative approaches for discovering new therapeutic assets, such as systematic screening of already approved drug molecules and employing microbiome-based research platforms, particularly for metabolic ailments. The company also explores therapeutic and diagnostic solutions across other fields, including neurology, gastroenterology, metabolic disorders, and women's health. Furthermore, Aptorum Group Limited also operates a medical clinic. Founded in 2010, Aptorum Group Limited maintains its corporate headquarters in London, United Kingdom.

Fuente - Link

Competidores

AEON BOLT CING CLRB COCP EVGN IMRN LYRA MBIO MRKR

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Woodside Energy Half-Year Report for Period Ended 30 June 2026

Woodside Energy Group (ASX: WDS) (NYSE: WDS):This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824

GuruFocus

MHI Receives Contract for APM System at Dubai's Al Maktoum International Airport

- Delivery of the world's largest APM system for airports, supporting the airport development plan to accommodate 260 million passengers annually- MHI Group is

GuruFocus

Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Amid Tariff Pressures

Revenue: $5 billion, up 4.4% on an FX-neutral basis.Adjusted Operating Margin: 24.9%, down 130 basis points versus the prior year.Adjusted Gross Margin: 54.3%,

GuruFocus

Aptorum Group Provides Update on DiamiR Biosciences Merger

Post-Merger company, Niki BioSolutions, Inc., to Trade on Nasdaq Under Ticker “NIKI”

GlobeNewsWire

Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer's Association International Conference

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, July 08, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced upcoming presentations at the annual Alzheimer's Association International Conference (AAIC), taking place at the Excel London Convention & Exhibition Centre, in London, UK, and online, on July 11-15, 2026, showcasing biomarker technologies from DiamiR's CLIA-certified, CAP-accredited clinical laboratory. Alidad Mireskandari, Ph.D.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2024-04-30	-2.7	0.514	3.214
2023-12-22	-2.6	-1.42519	1.17481
2023-04-28	-2.6	-2.21619	0.38381
2022-09-30	-3	-0.52831	2.47169
2022-04-29	-3.3	-2.51599	0.78401
2021-12-03	-3	-4.69107	-1.69107
2021-04-19	-3.1	3.9	7
2020-09-01	-2.5	-2.07109	0.42891